Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report) was upgraded by StockNews.com to a “sell” rating in a research report issued on Thursday. Several other analysts have also commented on LXRX. Leerink Partnrs reiterated an “outperform” rating on shares of Lexicon Pharmaceuticals in a report on Tuesday, April 30th. Needham & Company LLC reissued a “hold” […]
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Get Free Report) was the recipient of a significant growth in short interest during the month of April. As of April 30th, there was short interest totalling 23,440,000 shares, a growth of 16.5% from the April 15th total of 20,120,000 shares. Based on an average daily volume of 4,450,000 shares, […]
Lexicon Pharmaceuticals (NASDAQ:LXRX) Earns "Hold" Rating from Needham & Company LLC themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Rating Reaffirmed by Needham & Company LLC theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Lexicon Pharmaceuticals (NASDAQ:LXRX) Upgraded at StockNews.com theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.